We evaluated the prognostic significance of p185c-erbB-2 expression and ras gene mutations in all patients diagnosed with a pulmonary adenocarcinoma between 1982 and 1985 at the University of Iowa. pl85c-erbB-2 expression was detected in 15 cases (34%). A ras gene mutation was found in 16 cases (36%) and all were in codon-12 of K-ras. No N-ras mutations were identified. Both pl85c-erbB-2 expression and a K-ras mutation were found only in codon-12 and present in six cases (14%). By univariate analysis pl85c-erbB-2 expression was associated with shortened survival (P = 0.02) while the presence of a K-ras mutation was not (P = 0.16). Multivariate analysis by the Cox proportional hazards model, controlling for patient age and tumor stage, also continued to identify pl85c-erbB-2 expression as an independent unfavorable prognostic factor (P = 0.01). In this model a K-ras mutation also approached significance as a poor prognostic indicator (P = 0.06). The impact of both pl85c-erbB-2 expression and a K-ras mutation on survival was additive and highly significant (P = 0.004). This additive nature suggests that together these two markers identify a high-risk population of lung adenocarcinoma patients that may benefit from aggressive therapy. (J. Clin. Invest. 1994. 93:516-520.) 
Introduction
The leading cause of cancer death in the United States for both men and women is lung cancer. In 1992, it was estimated that 93,000 men and 53,000 women died of this disease (1) . Despite major advances in the treatment of many types of cancer over the past 25 yr, the 5-yr survival of all patients with lung cancer has improved minimally, from 5 to 11% N in blacks and 8 to 13% in whites (1) . Even in stage I lung cancer, where tumor is localized to the lung and presents the best chance ofcure, the long-term survival remains only 65% (2) . Therefore, it appears that better techniques are needed for more accurate staging and identification of those patients at risk for disease relapse. Our understanding of the molecular pathogenesis of lung cancer may now be at a point where novel strategies can be designed for this purpose. Preliminary data suggest that the identification of genetic or biochemical markers might allow physicians to predict a tumor's response to therapy or determine a patient's prognosis. Two markers that appear to have promise in this area are the presence of activating K-ras gene mutations and alterations in expression of the c-erbB-2 proto-oncogene.
Rodenhuis et al. first reported that a point mutation in codon 12 of the K-ras oncogene could be found in the tumors of approximately one third of all patients with pulmonary adenocarcinomas (3, 4) . This relatively high prevalence of K-ras activating mutations in lung adenocarcinomas has been independently confirmed by two laboratories (5, 6) . Slebos et al. determined the clinical importance of this finding in patients treated surgically for cure, by showing that lung adenocarcinomas with activating K-ras point mutations in comparison to mutation negative tumors tended to be smaller, less differentiated, and were predominantly stage 1 (7) . More importantly, survival analysis showed that the presence of an activating Kras point mutation in the tumor was a strong and unfavorable prognostic factor, with a shortened duration ofdisease-free survival and an increased number of deaths due to progressive cancer (7) . Even in patients with incurable disease treated palliatively, K-ras mutations continue to be a negative prognostic factor for overall survival (8) .
The proto-oncogene c-erbB-2 has also been shown to be expressed in a relatively large portion of lung tumors and, importantly, also appears to be associated with poor survival. Weiner et al. first reported that the c-erbB-2 protein product, p 1 85c-erbB-2, was expressed in -30% of human lung cancers (9) . This observation has been independently confirmed by other laboratories (10) (11) (12) (13) . The clinical importance of p1 85c-erbB-2 expression was studied by Kern et al., who found that expression of p 1 85c-erbB-2 identified a subset of patients who had a poor prognosis with shortened survival (14) . The association of p 1 85c-erbB-2 expression with diminished 5-yr survival has been confirmed in an Asian population (11), (30% for p1 85c-erbB-2 positive tumors vs. 52% for p1 85c-erbB-2 negative tumors, P < 0.01).
To date, the studies of p1 85c-erbB-2 expression and K-ras mutations in lung cancer have focused on the impact of these single abnormalities on survival. However, malignant transformation is the result of multiple genetic and biochemical abnormalities (15) , such as activation of proto-oncogenes (3, 4, (6) (7) (8) (9) (10) (11) (12) (13) (14) (16) (17) (18) (19) , tumor suppressor gene inactivation (18, (20) (21) (22) (23) (24) , and chromosomal changes (25) . Therefore, the effect of multiple biologic markers (26) on survival may be particularly important in stratifying patients into more precise prognostic categories (27) . Given this line of reasoning, we have hypothe-sized that p185c-erbB-2 expression and K-ras gene mutations would both individually contribute prognostic information in patients with pulmonary adenocarcinomas. Furthermore, we have hypothesized that these two biologic markers would be interactive and the prognosis associated with the presence of both markers would be significantly worse than the sum of their individual contribution. Therefore, we retrospectively analyzed a series of resected lung cancers for pl85c-erbB-2 expression and activating K-ras gene point mutations and performed an independent chart review to identify important clinical parameters and survival. Our data are the first to show the interactive nature and prognostic capabilities of these abnormalities; patients with pulmonary adenocarcinomas that express p1 85c-erbB-2 and harbor an activating K-ras point mutation have a significantly shortened survival than patients whose tumor has none or only one of the markers. However, although these tumor markers independently contribute to survival, our results suggest that these tumor markers do not appear to interact in a multiplicative fashion. Methods Study population. We limited our study population to those individuals who underwent resection or open biopsy procedures at the University of Iowa Hospitals and Clinics between 1982 and 1985. This approach was chosen so that we could precisely stage the lung tumor based on operative findings and allow adequate clinical follow-up time. Adenocarcinomas were identified by morphological and immunohistochemical characteristics (28) . Between 1982 and 1985, a total of 46 cases of pulmonary adenocarcinoma were resected or underwent an open biopsy procedure at the University ofIowa Hospitals and Clinics. 44 cases were studied; 2 cases had inadequate tissue specimens available for analysis and were not included. The p1 85c-erbB-2 expression status of 26 of these patients' adenocarcinomas has been previously reported ( 14) . Survival data on these patients have been updated and included in this analysis. Various clinical parameters ( 14) were obtained through chart review by an independent reviewer unaware ofthe results of the laboratory analysis. The median follow-up time for all patients was 170 wk (range, 10-428 wk). Standard criteria as set forth by the International Staging System for Lung Cancer (2) were used to determine characteristics ofthe primary tumor, regional lymph nodes, metastases, and surgical stage.
Identification ofpl85c-erbB-2. DBW-2, a polyclonal anti-p 1 85c-erbB-2 antiserum, was used. This antibody has been previously characterized (9, 14, 29) . Sections (3) (4) Mm) were cut from paraffin-embedded, formalin-fixed tissue blocks, placed on pretreated (Probe-on;
Fisher Scientific, Pittsburgh, PA) glass slides, dried at 370C overnight followed by 60'C for 30 min, and exposed to xylene for 5 min (three times). Tissues were rehydrated in decreasing concentrations of ethanol ( 100, 95, and 70%) for 2 min (twice), rinsed in distilled water, and endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in methanol (3 min). Slides were washed in PBS (20 min), excess liquid was blotted off, and non-immune goat serum (Vector Laboratories Inc., Burlingame, CA) was applied to reduce nonspecific background staining (20 min). The serum was drained and rabbit p1 85c-erbB-2 antiserum or a negative control applied (60 min ). Slides were rinsed with PBS and drained, and a biotin-conjugated goat anti-rabbit antibody (Vector Laboratories) was added. After 30 min, the slides were again rinsed with PBS, avidin was applied for 30 min, the slides were rinsed in PBS, diaminobenzidine (Aldrich Chemical Co., Milwaukee, WI) was added (30 min), and, again, the slides were rinsed with water and counterstained with Harris hematoxylin. After the counterstain, the tissue was dehydrated with increasing solutions of ethanol (70, 95, and 100%) for 2 min (twice) followed by clearing in xylene and mounting.
Positive controls of formalin-fixed, paraffin-embedded human lung were used with each staining reaction. Negative controls consisted of tissue sections from the paraffin-embedded lung cancer block to be studied for pl85c-erbB-2 expression treated with an irrelevant antibody (rabbit anti-mouse IgG; Vector Laboratories). All microscopic analyses were performed by the same pathologist (R. A. Robinson). A tissue specimen exhibiting membrane, or membrane and cytoplasmic reactivity with DBW-2 antiserum, throughout the tissue section was considered positive. No reactivity or cytoplasmic reactivity without membrane localization was considered negative.
DNA Isolation and amplification ofras-specific sequences by PCR. This procedure has been previously published (30, 31 ) . A 5-Mm section was cut from each tissue block and collected in an Eppendorf reaction tube. 300 Ml oflysis buffer was added ( 10 mM Tris HCl, pH 8.0, 50 mM KCl, 2.5 mM MgCl2, 0.01% (wt/vol) gelatin, 0.5% Tween 80, and 0.1 mg/ml of proteinase K). The samples were incubated for 18-24 h at 370C and then centrifuged for 10 min at 12,000 rpm. The supernatant was pipetted into a new tube, and used for amplification.
PCR amplification was done in a 50-70 Ml reaction volume using 1 . Two different sets of amplimers were used to amplify the K-ras oncogene, each set amplifying different regions around codon 12 (set 1: 5'-GGCCTGCTGAAAATGACTGA-3', and 5'-TGATTCTGAATT-AGCTGTAT-3'; set 2: 5'-GACTGAATATAAACTTGTGG-3'and 5'-CTATTGTTGGATCATATTCG3'). 25 Ml of sterile water with a drop of paraffin oil was added to the DNA samples, and the tubes were incubated at 100°C for 10 min to inactivate the proteinase K and denature the DNA. Then 25 Ml of the 2x amplification mixture was added, and the amplification reaction started. Amplification was done for 35 cycles at the following temperatures: 94°C for 30 s, 54°C for 30 s, and 72°C for 60 s in a Dri-block device (Techne Corp., Cambridge, UK). After amplification, the paraffin oil overlay was removed by adding 150 Ml of ether to each tube, and mixing. The two phases were allowed to separate and the top layer containing the paraffin oil/ether was removed.
Detection ofthepoint mutations by oligodeoxynucleotide hybridization. Hybridization membranes (Nytran-N, Schleicher & Schuell, Dassel, Germany) were pretreated with lOX SSC (lx SSC is 150 mM NaCl, 15 mM Na citrate at pH 7.6) and dried. For each oligodeoxynucleotide probe, one membrane was cut and attached to a glass plate. PCR samples were then sequentially denatured by incubation at 100°C for 1-2 min, and I-Ml portions were dotted on to the membranes. The membranes were dried and the DNA cross-linked by exposure to ultraviolet irradiation for 2 min. Each membrane was separately hybridized in a minimal volume of hybridization solution (3 M tetramethylammonium chloride, 50 mM Tris HCI, pH 7.5, 5 mM ethylenediaminetetraacetate, 1% SDS and 1% (wt/vol) milk protein [Protifar, Nutricia, The Netherlands]). Radioactive oligodeoxynucleotide probes were prepared for every possible point mutation in the ras gene to be investigated. Exact nucleotide sequences of these probes have been described previously (30, 3 1 ). Labeling reactions contained 5 pmol ofoligodeoxynucleotide (33 ng of a 20-mer), 10 MCi (3.3 pmol) of a [32P]ATP (Amersham Inc., Amersham, UK), 50 mM Tris HCI, pH 7.5, 8 mM MgCl2, 5 mM ,B-mercaptoethanol, 200 U/ml of T4 polynucleotide kinase (Boehringer Mannheim, Mannheim, Germany), in a 5-Ml reaction volume. Incubation was done for 30 min at 37°C, and the labeled oligodeoxynucleotide separated from the nonincorporated nucleotides by spindialysis. Hybridization was performed with 0.1 pmol (-. 0.5 ng of a 20-mer) of labeled oligodeoxynucleotide for every 10 cm2 membrane for at least I h at 56°C. The membranes were then washed at 63°C in 5x SSPE ( lx SSPE is 180 mM NaH2PO4, 1 mM EDTA) and 0.1% SDS for 20 min, and subsequently with 2x SSC at room temperature to remove the remaining SDS. Perfectly hybridizing oligodeoxynucleotide sequences are retained on the membranes, and were detectable by autoradiography at -70°C. Statistical analysis. The relationship between the cumulative probability of survival and a variety of clinical variables, including the ex-C-erbB-2, K-ras, and Survival ofPatients with Adenocarcinomas 517 pression of pl85c-erbB-2 and K-ras mutations, was determined by using the log rank test, as described by Kaplan and Meier (32) . Censoring was performed for subjects who were either lost to follow-up or were followed for less time than the longest survivor. The clinical factors that were significantly associated with the cumulative probability of survival were tested in a hierarchical multivariate survival analysis, as described by Cox and Oakes (33) . All interactions were tested among clinical factors that were found to be independently associated with survival.
Results
Prevalence of c-erbB-2 expression and codon 12 K-ras mutations in human lung cancer. We chose to analyze only pulmonary adenocarcinomas, as previous analyses of squamous cell lung cancer did not identify a high prevalence of K-ras mutations or clinical importance of pl 85c-erbB-2 expression (3, 4, 7, 9, 14) . Our study population consisted of patients with relatively early stages of lung cancer who averaged 62 yr of age (Table I) . Interestingly, 68% ofour patients died ofprogressive lung cancer, with their median survival being of24 wk. Among our patients with adenocarcinoma of the lung, p1 85c-erbB-2 was expressed in 15 of the 44 samples analyzed (34%), and K-ras activating point mutations were present in 16 tumors (36%), as noted in Table I . All point mutations were found in K-ras codon 12, with no mutations found in K-ras codon 13, 61, or N-ras. The predominant point mutation was a G-T transversion in position 1 of codon 12 (glycine [GGT] --cysteine [TGT]; 10 of 16, 62.5%), with a G-T transversion in position 2 occurring in 12.5% of the cases (glycine [GGT] valine [GTT]; 2 of 16) and a G-A transition in position 2 in 25% of the cases (glycine [GGT] --aspartic acid [GAT]; 4 of 16). 9 of 15 tumors with abnormal pl85c-erbB-2 expression had a wild type K-ras gene. 10 of 16 tumors with an activating point mutation in the K-ras gene did not express p1 85c-erbB-2. Six carcinomas expressed pl85c-erbB-2 and harbored an activated K-ras gene. Univariate analyses were performed using the Cox proportional hazard method. As shown in Table II , numerous patient and tumor characteristics significantly increased a patient's risk of early death. As expected, many important clinical characteristics, including weight loss, tumor size, the presence of metastases, and surgical stage, were related to the probability of survival in patients with adenocarcinoma. pl85c-erbB-2 expression was associated with a 2.4-fold increase in the patient's relative risk of dying as compared to those tumors that did not express p1 85c-erbB-2 (P = 0.02). The presence of any codon 12 K-ras point mutation carried a 1.7-fold increased risk of dying that did not reach statistical significance (P = 0.16). Specific K-ras point mutations were also examined to determine ifany individual mutation carried a worse prognosis than the mutations considered as a group. The G to A transition was associated with a slightly higher hazard ratio (2.8, 95% confidence interval 0.8, 9.9) that also did not achieve statistical significance (P = 0.10).
Multivariate analyses were performed to determine the independent contribution ofpl85c-erbB-2 expression and K-ras mutations in patients with adenocarcinoma of the lung, after controlling for other factors known to affect survival. Multivariate models were developed to test all the clinical variables, specifically examining the relationship between pI85c-erbB-2 expression, K-ras mutation, and survival. Surprisingly, variables beyond p185c-erbB-2 expression, K-ras mutation, age, and tumor stage failed to significantly contribute to the overall fit of the model. Two models were found to best represent the data (Table III) . In model I, when controlling for patient age and tumor stage, both p1 85c-erbB-2 expression and the presence of an activating K-ras mutation were associated with survival. Although the presence of a K-ras point mutation was associated with an excess risk ofdying (hazard ratio = 2.1 ), this association did not achieve statistical significance in a twotailed test with the 95% confidence interval still including 1. In model II, we examined the multiplicative effect on survival of both abnormalities present in a single carcinoma (Table III) . The combination ofboth factors in a single tumor had an additive effect resulting in a profound impact on patient survival, with a hazard ratio of 4.4 (95% confidence interval 1.6, 12.3, P = 0.004). The individual and combined impact of pl85c-erbB-2 and K-ras on survival is further illustrated in Fig. 1 . Kaplan-Meier survival curves suggest that patients with either p185c-erbB-2 expression or a K-ras point mutation have a 
Discussion
This work is the first analysis in lung cancer of the interaction oftwo known prognostic markers, c-erbB-2 expression and ras gene mutation, attempting to stratify patients into more accurate prognostic groups. Our results demonstrate that tumor stage was the single most important prognostic factor in patients with adenocarcinoma ofthe lung. However, after controlling for the stage of the tumor, pl85c-erbB-2 expression was significantly related to diminished survival and the K-ras point mutation tended to be associated with diminished survival. More importantly, the combination of these two factors on survival identifies a population with a poorer prognosis when compared to all other subjects with adenocarcinoma of the lung. The poorer survival of these patients whose tumors had 1.00 both abnormalities than of those patients who had only one abnormality reinforces the independent effect of these biologic tumor markers on survival. Our results further indicate that these independent prognosticators do not appear to interact biologically. The role of p1 85c-erbB-2 and K-ras mutations in pulmonary tumorigenesis remains unclear. Both abnormalities have been found in roughly one third of all pulmonary adenocarcinomas examined; and, as shown in this study, the abnormalities overlap, with both being present in 14% ofcases. Their role, if any, in the transformation of normal pulmonary epithelium in vivo is not known. Regardless of their role in tumorigenesis, they clearly serve an important function as prognostic markers and potential guides for therapy. The prevalence of p 1 85c-erbB-2 expression or a K-ras mutation in our study population agrees with other studies that have examined these markers. In addition, the effect of p 1 85c-erbB-2 expression on survival is also supported by our previous study and that of Tateishi et al. ( 12, 14) . However, our results suggest that K-ras mutations did not play as significant a role in predicting survival in our patient population, as has been suggested by Slebos et al. (7) or Mitsudomi et al. (8) . These investigators observed that K-ras was significantly associated with survival in patients with adenocarcinoma of the lung. Although our results suggest a trend toward significance, we did not find K-ras to be statistically associated with survival. There are important differences in the patient populations of these three studies that most likely account for this discrepancy. Slebos et al. studied stage I, II, and lila patients treated with curative intent by complete surgical resection. Our study involved all patients diagnosed with adenocarcinoma of the lung during the study period, regardless of treatment intent, and included patients with stage IV tumors. Mitsudomi et al. studied a broader range of histologic tumor type than this study, including nonadenocarcinomas, which represented 42% of the K-ras mutations. Furthermore, only 58% of the mutations found were at codon 12 of K-ras, while all of the mutations in our p185c-erbB-2 K-ras Expression Mutation ---------II II population were at codon 12. In addition, they had to be able to establish a cell line from the tumor to be included in the analysis, which in itself may prove to be a poor prognostic indicator. Our multivariate models suggest that the expression of c-erbB-2 and K-ras mutations independently contributes to survival in patients with adenocarcinoma of the lung. However, these two prognostic factors appear to function in parallel and do not interact biologically, since the impact ofboth factors on survival is additive, not multiplicative. This would suggest that these two factors have independent contributions to the invasive and metastatic qualities of adenocarcinoma of the lung. Identifying the tumor biology inherent in these prognostic biomarkers may provide new avenues for directed and combined therapeutic interventions.
The presence ofa K-ras point mutation or c-erbB-2 expression may be of more value than just as a prognostic marker. Recent reports suggest that tumors that acquire a K-ras point mutation in vitro may become resistant to radiation and to several drugs, including cisplatin (34, 35) . Whether this effect is relevant to patients with lung cancer is not clear. However, the poorer survival of those patients with both abnormalities suggests that these biological markers may independently contribute to drug resistance.
Our results indicate that further studies are needed to evaluate the clinical and biological importance of tumors expressing pl85c-erbB-2 and K-ras point mutations. In particular, the relation to specific therapeutic interventions may allow us to extend survival in this high-risk population of patients with adenocarcinoma of the lung.
